CD8A and COVID-19: Furthermore, the therapeutic effects of NDV-RBD in A375 tumors engrafted in NCG mice receiving transfer of convalescent COVID-19 patient PBMCs were almost diminished upon CD8+ or CD4+ T cell depletion (Extended Data Fig. 10d,e).